The Novo subsidiary has invested in a $22.5m round for the biotechnology company that also featured Sofinnova Partners and InnoBio.

Lysogene, a France-based gene therapy biotechnology company, has raised €16.5m ($22.5m) in its series A round from a consortium including a venturing unit operated by Denmark-based healthcare investment foundation Novo.

Venture capital firm Sofinnova Partners and InnoBio, a €139m ($189m) venture capital fund managed by Bpifrance, invested alongside Novo Seeds in the round.

The French government has subscribed to 37% of InnoBio through the FSI organisation, together with pharmaceutical companies including Sanofi-Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and…